BioWorld Asia

Sep. 27, 2006

Merck KGaA Buying Serono, Giving CHF16.6B Valuation

Merck KGaA agreed to acquire a controlling stake in Serono SA by purchasing the Bertarelli family's shares in the company, which represent 64.5 percent of its equity and 75.5 percent of its voting rights. (BioWorld International) Read More

GPC Biotech Shares Jump On Prostate Cancer Study Results

Proteomics Approach Could Bring Rapid Dipstick For TB

Another European Agenda For Innovative Medicines

Jerini Shares Plummet On Mixed Phase III Trial News

India's Avesthagen Seeking VC Money, Eyeing 2008 IPO

BioAlliance Pharma Reports Phase I/II Doxorubicin Data

Europe Trails U.S. In Tech Transfer; Patents Lag, Too

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...